Evidence map›Paper›PMID 23830960›Full record

ArticleJournal of stroke and cerebrovascular diseases : the official journal of National Stroke Association2013

Acute decrease in serum magnesium level after ischemic stroke may not predict decrease in neurologic function.

James E Siegler, Amelia K Boehme, Karen C Albright, Sami Bdeir, Anoop K Kar, Leann Myers, T Mark Beasley, Sheryl Martin-Schild

Abstract read
In one paragraph

Article in Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

James E SieglerStroke Program, Department of Neurology, Tulane University Hospital, New Orleans, Louisiana.
Amelia K Boehme
Karen C Albright
Sami Bdeir
Anoop K Kar
Leann Myers
T Mark Beasley
Sheryl Martin-Schild

Funding

RESEARCH TRAINING COREP60MD000502 · NIMHD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI PARTRIDGE, EDWARD E. · 2003 to 2016
$16.2M
UAB Health Services Research (HSR) Training ProgramT32HS013852 · AHRQ · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LEVITAN, EMILY B, MUGAVERO, MICHAEL J · 2003 to 2024
$8.0M
AHRQ HHS 5 T32 HS013852-10AHRQ HHS HS013852AHRQ HHS HS013852-07AHRQ HHS T32 HS013852NIMHD NIH HHS 3 P60 MD000502-08S1NIMHD NIH HHS P60 MD000502
6 · The paper itself

Abstract

backgroundHigher serum levels of magnesium (Mg2+) may contribute to improved outcome following ischemic stroke, and this may be related to vessel recanalization. Patients with low or normal serum magnesium levels during the acute phase of ischemic stroke may be more susceptible to neurologic deterioration (ND) and worse outcomes.

methodsAll patients who presented to our center within 48 hours of acute ischemic stroke (July 2008 to December 2010) were retrospectively identified. Patient demographics, laboratory values, and multiple outcome measures, including ND, were compared across admission serum Mg2+ groups and change in Mg2+ from baseline to 24-hour groups.

resultsThree hundred thirteen patients met inclusion criteria (mean age: 64.8 years, 42.2% female, 64.0% black). Mg2+ groups at baseline were not predictive of poor functional outcome, death, or discharge disposition. Patients whose serum Mg2+ decreased during the first 24 hours of admission were also not at greater odds of ND or poor outcome measures compared with patients with unchanging or increasing Mg2+ levels.

conclusionsOur results suggest that patients who have low Mg2+ at baseline or a reduction in Mg2+ 24 hours after admission are not at a higher risk of experiencing ND or poor short-term outcome. Ongoing prospective interventional trials will determine if hyperacute aggressive magnesium replacement affords neuroprotection in stroke.

Indexed as

AdultAgedAged, 80 and overBiomarkersBrain IschemiaChi-Square DistributionDisability EvaluationDown-RegulationFemaleHumansLogistic ModelsMagnesiumMaleMiddle AgedNervous SystemNeurologic ExaminationBiomarkersMagnesiumischemiamagnesiumneurologic deteriorationneuroprotectionStroke

Identifiers

PMID23830960
PMCPMC3818504

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.